An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

N/AApproved For MarketingNCT01833039

Janssen Biotech, Inc.

Overview

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.

Study Type

EXPANDED_ACCESS

Conditions

Relapsed or Refractory Mantle Cell Lymphoma

Interventions

IbrutinibDRUG

Ibrutinib

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible. Exclusion Criteria: * Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible. * Patients previously treated with ibrutinib are not eligible. * Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.

Locations (51)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Phoenix, Arizona, United States

Unnamed facility

Duarte, California, United States

Unnamed facility

Los Angeles, California, United States

Unnamed facility

Stanford, California, United States

Unnamed facility

Denver, Colorado, United States

Unnamed facility

Norwalk, Connecticut, United States

Unnamed facility

Stamford, Connecticut, United States

Unnamed facility

Washington D.C., District of Columbia, United States

Unnamed facility

Miami Beach, Florida, United States

Unnamed facility

Ocala, Florida, United States

...and 41 more locations